trial · primary record
Deutenzalutamide
Prostate Cancer (Adenocarcinoma)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2035-01 |
| Primary endpoint | Pathological Complete Response or Minimal Residual Disease (pCR/MRD) Rate |
| Registry ID | NCT07907653 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:37.511Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07907653
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.